bs 20482r  (Bioss)

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 1 ANLN expression in breast cancer. Examples of immunohistochemical staining patterns of ANLN in breast cancer tissue shows nuclear expression in a variable fraction of tumor cells. Examples correspond to the different scores for nuclear fraction (NF) used in the analysis. 0–1% (a), 2–10% (b), 11–25% (c), 26–50% (d), 51–75% (e) and 76–100% (f). Scale bars 100 μm

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 4 Association of ANLN mRNA expression with survival. Kaplan-Meier survival curve based on gene-expression data and survival information from a publicly available DNA microarray dataset showed that high ANLN expression was significantly associated with poor survival

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Expressing, Gene Expression, Microarray

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 5 Association of ANLN expression with cell cycle arrest. Flow cytometry-generated data showed that ANLN depletion lead to a significant accumulation of cells in the G2/M phase of the cell cycle 3 days after siRNA knockdown, in both SKBR3 and T47D cells

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Expressing, Flow Cytometry, Generated, Knockdown

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 6 Influence of ANLN on cell morphology. Immunofluorescent staining of SKBR3 and T47D breast cancer cell lines showed efficient knockdown of ANLN nuclear expression by two different siRNAs. ANLN siRNA knockdown induced a larger cell size and cells with multiple nuclei compared to controls in both cell lines examined. ANLN was stained with FITC (green), nuclei were stained with DAPI (blue) and actin filaments were stained with TRITC (red). Scale bars 30 μm

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Staining, Knockdown, Expressing

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 7 Association of ANLN expression with senescence. Transient knockdown of ANLN expression induced significant levels of cellular senescence compared to control in SKBR3 cells up to 5 days after initiation of ANLN depletion. Similar, but not significant, result was observed for T47D cells. Scale bars 60 μm

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Expressing, Knockdown, Control

Journal: BMC cancer

Article Title: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

doi: 10.1186/s12885-016-2923-8

Figure Lengend Snippet: Fig. 8 Influence of ANLN on cell cycle associated proteins. Western blot analysis showed efficient knockdown of ANLN expression by two different siRNAs. Overall, ANLN siRNA knockdown resulted in lower expression of cyclin D1, cyclin A2 and cyclin B1compared to controls in SKBR3 and T47D breast cancer cell lines. B-actin was used as a loading control

Article Snippet: The specific target binding of the primary affinity purified polyclonal antibody towards ANLN (HPA005680, Atlas Antibodies, Stockholm, Sweden) was initially validated according to standardized procedures used in the Human Protein Atlas (http://www.proteinatlas.org) with assays including reverse phase protein array, Western blot, IHC, immunofluorescence (IF) and comparing results with bioinformatic predictions and published data [22].

Techniques: Western Blot, Knockdown, Expressing, Control